Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 10,333 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all
Completed Phase 3 Interventional

Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)

NCT01411280
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
methylphenidate
Drug
Lead sponsor
Temple University
Other
Eligibility
6 Years to 16 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 25, 2026, 6:23 AM EDT
Recruiting No phase listed Observational

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

NCT06512454
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Gainesville, Florida • Charleston, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The PREFORM Study: Rotational Fractional Resection for Submental Contouring

NCT03966924
View directory record Official record
Conditions
Skin Laxity, Lipodystrophy
Interventions
Rotational fractional resection (1.5mm Diameter Device)
Device
Lead sponsor
Recros Medica, Inc.
Industry
Eligibility
30 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements

NCT03534986
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
International Biophysics AffloVest, Hill-Rom The Vest, Respirtech inCourage, Electromed SmartVest
Device
Lead sponsor
International Biophysics Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Kissimmee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 25, 2026, 6:23 AM EDT
Recruiting Phase 3 Interventional

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

NCT07366086
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Vitamin D, Calcium
Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 19 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 6:23 AM EDT
Recruiting Not applicable Interventional

Lung Transplant READY CF 2: CARING CF Ancillary RCT

NCT06032273
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Investigator-designed lung transplant education website
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Yogic Breathing Changes Salivary Components

NCT02108769
View directory record Official record
Conditions
Alzheimer Disease, Neurodegenerative Diseases, Cancer
Interventions
Yogic Breathing, Attention Control
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 25, 2026, 6:23 AM EDT
Completed No phase listed Observational

Farber Disease Natural History Study

NCT03233841
View directory record Official record
Conditions
Farber Disease, Farber's Disease, Farber Lipogranulomatosis, Acid Ceramidase Deficiency, Ceramidase Deficiency, N-Laurylsphingosine Deacylase Deficiency, ASAH1 Mutation
Interventions
Not listed
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Oakland, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00044954
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
14
States / cities
Denver, Colorado • Orlando, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 25, 2026, 6:23 AM EDT
Terminated No phase listed Observational

Radiofrequency Ablation of Ectopic Atrial Tachycardia

NCT00267982
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

NCT03406780
View directory record Official record
Conditions
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions
CAP-1002, Placebo
Biological · Drug
Lead sponsor
Capricor Inc.
Industry
Eligibility
10 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Not applicable Interventional

The Men Are Now United Program

NCT03208686
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Intervention Group
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 25, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

NCT01465386
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
Interventions
bortezomib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

NCT03576469
View directory record Official record
Conditions
CVI - Common Variable Immunodeficiency
Interventions
C1-esterase inhibitor [recombinant] (C1-INH-R)
Biological
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Phase 2Phase 3 Interventional

Saline Hypertonic in Preschoolers + CT

NCT02950883
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Active Treatment Group 7% Hypertonic Saline, Control Group 0.9% Isotonic Saline
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
7
States / cities
Aurora, Colorado • Indianapolis, Indiana • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 25, 2026, 6:23 AM EDT
Terminated Phase 1 Interventional

FAAH Inhibitor Trial for Adults With Tourette Syndrome

NCT02134080
View directory record Official record
Conditions
Tourette Syndrome
Interventions
PF-04457845, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 25, 2026, 6:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

NCT05518188
View directory record Official record
Conditions
Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation, SPG50, Spastic Paraplegia
Interventions
MELPIDA
Biological
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
4 Months to 10 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 6:23 AM EDT
Active, not recruiting Not applicable Interventional

Comparing Surgical and Endovascular Arteriovenous Fistula Creation

NCT05654103
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
endoAVF, surgAVF
Device · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 99 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00003116
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
4 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03924947
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Ventura, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

Citalopram to Enhance Cognition in HD

NCT00271596
View directory record Official record
Conditions
Huntington Disease, Chorea, Executive Dysfunction
Interventions
20mg daily citalopram, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 25, 2026, 6:23 AM EDT
Completed Not applicable Interventional Results available

Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period

NCT04452188
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome, Total Anomalous Pulmonary Venous Return, Truncus Arteriosus, Pulmonary Atresia With Ventricular Septal Defect, Transposition of the Great Arteries, Double Outlet Right Ventricle, Subpulmonary VSD, Tetralogy of Fallot, Double Outlet Right Ventricle With Subaortic Ventricular Septal Defect and Pulmonary Stenosis, Cardiopulmonary Bypass
Interventions
Normoxia (with controlled re-oxygenation), Standard of care ventilation
Other
Lead sponsor
University of Michigan
Other
Eligibility
Up to 29 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 25, 2026, 6:23 AM EDT
Approved For Marketing No phase listed Expanded access

BMN 110 US Expanded Access Program

NCT01858103
View directory record Official record
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 25, 2026, 6:23 AM EDT